Company news
Novavax, Inc. (NASDAQ:NVAX) news
Every Novavax, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccina...
August 28, 2026
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
June 1, 2026
Novavax to Participate in BofA Securities 2026 Health Care Conference
May 7, 2026
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
May 6, 2026
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
March 30, 2026
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030...
March 13, 2026
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
February 26, 2026
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 19, 2026
Novavax Announces Entering into a License Agreement with Pfizer
January 20, 2026
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Novavax to Participate in Jefferies London Healthcare Conference
November 12, 2025
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
November 6, 2025
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
November 4, 2025
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
October 22, 2025
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million ...
October 7, 2025
Novavax Announces Progress on Sanofi Agreement
September 30, 2025
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
September 4, 2025
Novavax to Participate in the Cantor Global Healthcare Conference
September 3, 2025
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
August 27, 2025
Novavax Announces Convertible Debt Refinancing
August 21, 2025
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
August 6, 2025
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
July 24, 2025
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolera...
June 11, 2025
Novavax to Participate in Upcoming Investor Conferences
May 29, 2025
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
May 19, 2025
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
May 8, 2025
Novavax to Participate in BofA Securities 2025 Health Care Conference
May 7, 2025
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
May 5, 2025
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
May 1, 2025
Novavax Appoints Charles Newton to Board of Directors
April 29, 2025
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
April 15, 2025
Novavax Announces Changes to Board of Directors
March 11, 2025
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
February 27, 2025
Novavax to Participate in Upcoming March Investor Conferences
February 27, 2025
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27,...
February 20, 2025
Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.
January 23, 2025
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
December 13, 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
December 10, 2024
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
December 4, 2024
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
November 12, 2024
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
November 11, 2024
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
November 4, 2024
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
October 16, 2024
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
October 9, 2024
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
September 25, 2024